Thursday, 25 April 2013

Stemedica reaches agreement with Kalbe Farma for clinical trials in Asia

Stemedica Cell Technologies announced today that it has reached an agreement with the Stem Cell and Cancer Institute, a division of PT Kalbe Farma (Kalbe) that makes Kalbe the exclusive licensor of Stemedica’s patented mesenchymal and neural stem cells for use in clinical trials in Indonesia, Philippines and Thailand.

According to the agreement, Kalbe will be responsible for organising clinical trials in the aforementioned countries and also grants Kalbe with first rights of refusal in other Southeast Asian countries including:
  • Brunei
  • Cambodia
  • Laos
  • Malaysia
  • Myanmar
  • Singapore
  • Vietnam

“We are honoured to be associated with a company of Kalbe’s calibre; a company that strictly adheres to the ethical and regulatory guidelines in medicine.” said Nikolai Tankovich, President and Chief Medical Officer of Stemedica.


Promotional video of Stemedica


You can read the official press release here

No comments:

Post a Comment

Please note that we dont offer any kind of medical advice. Questions requesting specific medical advice (e.g. where can I get this treatment, will this cure XXX condition, etc) will be published but most probably ignored by the administrators. :)

Note to spammers: You shall not pass. If you really want a link from us then consider making a stem cell related guest post !